Nehal Chopra is a graduate from the Wharton School of the University of Pennsylvania. In 2011, Tiger Management, led by Julian Robertson, seeded Nehal Chopra’s Ratan Capital. She has also worked as at UBS and Lehman Brothers Holdings and then joined hedge fund firms Dmitry Balyasny’s Balyasny Asset Management and Ramius Capital Group, managed by Cowen Group. She launched Ratan Capital Management in 2009, which is a long-short equity fund. The fund exited 2013, with a portfolio value of $411.29 million, up from $336.74 million in the third quarter.
In its latest 13F filing, Ratan Capital Management LP, has disclosed holding 474,200 shares of Valeant Pharmaceuticals International (NYSE:VRX), up from 409,700 shares held in the third quarter of 2013, . The fund’s tweak in the position has upped the value of the holding to $55.67 million from $42.75 million reported previously.Early this month, the multinational specialty pharmaceutical company has entered into a definitive agreement to acquire PreCision Dermatology, Inc for a total sum of $500 million.
Next on the list is the Massachusetts based CIRCOR International, Inc (NYSE:CIR). The fund now owns 603,000 shares of the company, worth $48.71 million. The stake has been significantly increased from 496,600 shares held in the third quarter. CIRCOR International, Inc (NYSE:CIR) manufactures, designs and markets valves and other highly engineered products. In the second week of February, the company declared cash dividend of $0.038 per share, payable on March 14, 2014.
In Post Holdings, Inc. (NYSE:POST), the manufacturer, marketer and distributor of branded ready-to-eat cereals, Ratan has raised its stake to 820,100 shares, from 482,400 held earlier. The value of the stake amounts to $40.41 million. Post Holdings Inc exited the previous quarter with earnings of $0.02 per diluted share.
Forest Laboratories, Inc. (NYSE:FRX) occupied the fourth spot. The fund holds 639,091 shares of the company, a significant increase from 471,400 shares held in the third quarter. The value of the stake holding amounts to $38.35, which is equivalent to 9.32% of the fund’s equity portfolio. The New York based company is developer, manufacturer and seller of branded ethical drugs. Last week, Actavis Plc announced that it will acquire Forest Laboratories, Inc (NYSE:FRX) in an equity and cash transaction worth $25.0 billion.
Ratan Capital Management held the fifth largest stake in Allergan Inc (NYSE:AGN), a multi-specialty healthcare company. The fund significantly upped the position to 289,000 shares in the fourth quarter of last year from 150,000 shares held in the previous quarter. The value of its holdings totaled to $32.11 million, which is equivalent to 7.8% of the fund’s equity portfolio.